Drug Profile
Mirdametinib - SpringWorks Therapeutics
Alternative Names: PD-0325901; PD-325901Latest Information Update: 12 Mar 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Developer AstraZeneca; BeiGene; BIOENSIS; Memorial Sloan-Kettering Cancer Center; Pfizer; SpringWorks Therapeutics; St. Jude Childrens Research Hospital; University of Oxford
- Class Aniline compounds; Anti-inflammatories; Antineoplastics; Benzamides; Immunotherapies; Small molecules
- Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preregistration Neurofibromatosis 1
- Phase I/II Glioma; Solid tumours
- No development reported Cervical cancer; Chronic obstructive pulmonary disease
- Discontinued Breast cancer; Cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer
Most Recent Events
- 04 Mar 2024 Preregistration for Neurofibromatosis 1 (In adolescents, In children, In the elderly, Inoperable/Unresectable, In adults) in USA (PO)
- 04 Mar 2024 SpringWorks Therapeutics announces intention to complete NDA submission to the US FDA for Neurofibromatosis 1 in the second quarter of 2024
- 27 Feb 2024 SpringWorks Therapeutics receives patent allowance for mirdametinib in the US